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A randomized controlled trial of endovascular
aneurysm repair versus open surgery for
abdominal aortic aneurysms in low- to
moderate-risk patients
Jean-Pierre Becquemin, MD, Jean-Chistophe Pillet, MD, François Lescalie, MD, Marc Sapoval, MD,
Yann Goueffic, MD, Patrick Lermusiaux, MD, Eric Steinmetz, MD, and Jean Marzelle, MD, for the ACE
trialists, Creteil, France
Background: Several studies, including three randomized controlled trials (RCTs), have shown that endovascular repair
(EVAR) of abdominal aortic aneurysms (AAA) offered better early results than open surgical repair (OSR) but a similar
medium-term to long-term mortality and a higher incidence of reinterventions. Thus, the role of EVAR, most notably in
low-risk patients, remains debated.
Methods: The ACE (Anevrysme de l’aorte abdominale: Chirurgie versus Endoprothese) trial compared mortality and major
adverse events after EVAR and OSR in patients with AAA anatomically suitable for EVAR and at low-risk or intermediate-risk
for open surgery. A total of 316 patients with>5 cm aneurysms were randomized in institutions with proven expertise for both
treatments: 299 patients were available for analysis, and 149 were assigned to OSR and 150 to EVAR. Patients were monitored
for 5 years after treatment. Statistical analysis was by intention to treat.
Results:With a median follow-up of 3 years (range, 0-4.8 years), there was no difference in the cumulative survival free of death
or major events rates between OSR and EVAR: 95.9% 1.6% vs 93.2% 2.1% at 1 year and 85.1% 4.5% vs 82.4% 3.7%
at 3 years, respectively (P  .09). In-hospital mortality (0.6% vs 1.3%; P  1.0), survival, and the percentage of minor
complications were not statistically different. In the EVAR group, however, the crude percentage of reintervention was higher
(2.4% vs 16%, P < .0001), with a trend toward a higher aneurysm-related mortality (0.7% vs 4%; P  .12).
Conclusions: In patients with low to intermediate risk factors, open repair of AAA is as safe as EVAR and remains a more
durable option. (J Vasc Surg 2011;53:1167-73.)
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MRupture of abdominal aortic aneurysm (AAA) is a fre-
quent cause of cardiovascular death in industrialized coun-
tries. Prophylactic open surgical repair (OSR) is indicated for
large asymptomatic AAA in patients with acceptable operative
risk.However, despite improvements in surgical expertise and
anesthesia, the death toll after OSR remains significant. Paro-
From the Department of Vascular Surgery, Hopital Henri Mondor, Univer-
sity Paris XII.
This study was supported by a grant obtained from the French Ministry of
Health that covered the cost of the study. The sponsor had no role in
study design.
Competition of interest: J.P. Becquemin received fees for consulting and for
speaking from Cook, Medtronic, Gore, and Vascutek.
Additional materials for this article may be found online at www.jvascsurg.
org.
Reprint requests: Dr Jean-Pierre Becquemin, University of Paris, XII, VAS-
CULAR SURGERY, Hopital Henri Mondor, University Paris XII 51
avenue du 94000 Creteil, France (e-mail: jpbecquemin@hotmail.com).
The editors and reviewers of this article have no relevant financial relation-
ships to disclose per the JVS policy that requires reviewers to decline
review of any manuscript for which they may have a competition of
interest.
0741-5214/$36.00a
Copyright © 2011 by the Society for Vascular Surgery.
doi:10.1016/j.jvs.2010.10.124ii’s report raised hopes that endovascular repair of AAA
EVAR) might improve outcomes.1 Meta-analysis of retro-
pective studies as well as three prospective randomized con-
rolled studies (RCT) tended to confirm this hypothesis, at
east in the early stage.2-4
After health care provider authorizations and stent graft
eimbursements, the number of patients undergoingOSRhas
apidly declined while the number undergoing EVAR has
xpanded.5,6 However, rupture may still happen after EVAR,
nd reinterventions are not infrequent.3,4,7 As a consequence,
he long-term efficacy of EVAR is still debated.
The ACE (Anevrysme de l’aorte abdominale: Chiru-
gie versus Endoprothese) trial (http://ClinicalTrials.
ov, #NTC00224718) was conceived in 1998. This mul-
icenter, prospective randomized trial assessed the results of
SR vs EVAR in patients presenting with an asymptomatic
AA, deemed at low to moderate risk for surgery. We report
he final results of this trial, with amedian follow-up of 3 years.
ETHODS
Participants. Inclusion criteria combined anatomic
nd clinical assessment:
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May 20111168 Becquemin et al● Anatomic criteria were based on computed tomography
(CT) scan findings: AAA50mm inmen or45mm in
women, or common iliac artery aneurysm 30 mm and
upper neck free of major thrombus or calcifications and
at15mm in length and an angle between the neck and
the axis of the aneurysm60° and iliac arteries compat-
ible with the introducer sheath.
● Clinical assessment graded patients in categories 0 to 2
according to the comorbidity score of the Society for
Vascular Surgery/American Association for Vascular
Surgery (SVS/AAVS).8
Exclusion criteria were previous abdominal aortic sur-
gery, ruptured aneurysm, mycotic aneurysm, severe iodine
allergy, life expectancy deemed 6 months, or category 3
of the SVS/AAVS classification.
Centers fulfilled the recommendations issued in 2001
by the French Regulatory Agency for Medical Drug and
Device Safety, which required a minimal activity of 20 AAA
repairs/year and at least 8 EVAR procedures to be autho-
rized to performed EVAR. By the time the study started, at
least 30 EVAR procedures had been done in each center.
Interventions. The protocol did not recommend any
specific preoperative treatment (eg, -blockers or statins).
Prophylactic antibiotics were injected intravenously at the
beginning of the procedure. Intravenous heparin (0.5 mg/
kg) was administered before clamping or sheath insertion.
Aspirin (75mg/d) was given postoperatively to all patients.
Any bifurcated or aortouniiliac stent graft with a Euro-
pean Conformity mark and approved by the French Health
Security Agency could be used for EVAR. Access (cutdown
or percutaneous) and management of hypogastric arteries
(embolization, overlap by stent graft) were left to the
surgeon’s decision.
Surgical approach for transperitoneal or retroperitoneal
OSR, type of graft (polyester of polytetrafluoroethylene),
combined revascularizationof inferiormesenteric artery or hy-
pogastric artery, or both, were left to the surgeon’s decision.
Outcomes. The primary end point was death of any
cause and major adverse events, including myocardial in-
farction (defined by electrocardiogram signs, enzymes, and
troponin elevation), permanent stroke, permanent hemo-
dialysis, major amputation, paraplegia, and bowel infarc-
tion. Secondary end points included vascular reinterven-
tions and minor complications. Sexual impairment was
assessed at 1 year by asking for any alteration in sexual
function after treatment. No formal established question-
naire was used. Buttock claudication was defined by the
postoperative onset of a buttock pain that prevented a
normal walking activity (ie, occurring for a walking distance
of300 meters). Incisional complications included all wall
dehiscences and large abdominal wall palsy when the pa-
tient found it debilitating. Reinterventions for incisional
repair were not recorded.
Follow-up visits were scheduled at 1, 6, and 12months,
and yearly thereafter. In the EVAR arm, plain abdominal
radiography, duplex scan, and contrast CT scan were per- 2ormed at each evaluation. All events were collected in the
ase report form.
Study organization is summarized in Appendix 1 (online
nly). A multidisciplinary independent committee validated
ll end points.
Sample size. With the hypothesis of a 2-year 30%
eduction of the incidence of death and major adverse
vents in the EVAR group (, 5%;  risk, 10%), 600
atients were required. Although the study was designed in
999, it started in 2003 due to (1) conflicts between the
inistry of Health and the National Healthcare Reim-
ursement Organization, (2) structural changes in regula-
ory agencies and recommendations (temporary limitation
o high-risk patients), and (3) insurance issues between
linical Research Direction and the centers. Because of a
low inclusion rate due to previously reported reasons,9 the
cientific committee stopped enrollment in March 2008
nd extended the follow-up up to 5 years. The trial ended in
pril 2009.
Randomization. Patient data in each center were
hecked by a multidisciplinary team (vascular surgeon, radiol-
gist, and anesthesiologist). After written informed consent
as obtained, the Clinical Research Unit of Henri Mondor
ospital performed randomization stratified by center. Arm
llocation was notified24 hours to the investigator.
Statistical methods. Analysis was performed by
ntention-to-treat. Patient characteristics, in-hospital post-
perative data, and outcome measure are expressed as
eans with standard deviation (SD) or as counts and
ercentage. Qualitative variables were compared using 2
est or Fisher test when appropriate. Quantitative variables
mean  SD) were compared using the t test. Overall
urvival was calculated from the date of inclusion until
eath, major adverse complication, or last follow-up.
vent-free survival of minor complication was calculated
rom the date of inclusion until minor complication, death,
ajor complication, or the last follow-up. Survival curves
ere estimated by the Kaplan-Meier method. Differences
etween the survival curves were tested for significance by
he log-rank test. All P values reported were two-sided.
ifferences between the results of comparative tests were
onsidered significant at P  .05. SPSS France 16.0 soft-
are (Bois Colombes, France) was used.
ESULTS
Between March 2003 and March 2008, 25 centers
Appendix 2) participated in the study. The mean number
f patients per center was 12  20 (range, 1-102).
A flow diagram (Fig 1) shows results of the randomiza-
ion and protocol deviations. Of 306 randomized patients,
were excluded from analysis because of withdrawal of
onsent. Intention-to-treat analysis was performed in 299
atients (149 allocated to OSR and 150 to EVAR): 277
92.6%) were treated according to randomization, 1 patient
id not undergo intervention, and there were 21 cross-
vers, mostly due to patient’s preferences. The crossover
ate was significantly higher in the OSR arm (11.4% vs
.7%; P  .01). Mean time from randomization to treat-
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Volume 53, Number 5 Becquemin et al 1169ment was 16.8  6.6 days (range, 1-29 days). Three
patients were lost to follow-up in the EVAR group (2%),
and five in theOSR group (3.3%). Patients were censored at
the last available follow-up.
Baseline data. There were 3 women (1.0%) and 296
men (99.0%). Mean age was 69  7 years (range, 49-83
years). Preoperative risk factors, SVS/AAVS scores, American
Society of Anesthesiologists classification, aneurysm classifica-
tion, and diameters are reported in Table I. Both groups were
similar at baseline, with the exception of a significantly higher
rate of category 2 coronary disease (16.8% vs 8.0%; P  .05)
and a more severe SVS/AAVS grading score (grade 2: 69.1%
vs 54.7%; P .01) in the OSR arm.
Intervention. General anesthesia was used in all oper-
ations, except for eight patients in the EVAR arm (four
local and four epidural anesthesia).
In the OSR arm, surgery was performed through a
midline incision in 70 patients, a transverse incision in 10,
and a retroperitoneal approach in 51. A tube graft was
inserted in 70 patients and a bifurcated graft in 61.
In the EVAR arm, four types of stent grafts were used:
Zenith (Cook, Inc, Bloomington, Ind) in 81 patients (71
bifurcated, 10 aortouniiliac), Talent (Medtronic Vascular,
Santa Rose, Calif) in 52 (41 bifurcated, 11 aortouniiliac),
Excluder (W. L. Gore and Assoc, Flagstaff, Ariz) in 9 (all
bifurcated), and Powerlink (Endologix, Irvine, Calif) in 4
(all bifurcated).
Operative details are summarized in Table II. EVAR
was associated with a shorter duration of intervention and
of ventilatory support, and less blood transfusion. As ex-
pected, X-ray exposure time and amount of contrast were
Fig 1. Flow diagram of the study.higher with EVAR. TPostoperative course. Table III summarizes the post-
perative outcomes. Three deaths occurred postopera-
ively, comprising two myocardial infarctions (one in each
roup) and one cardiac arrest after immediate conversion to
SR due to stent graft misdeployment. General complica-
ion and reintervention rates did not differ statistically. The
ean length of stay was 5.8  5.5 days after EVAR and
0.4  8.3 after OSR (P  .0001).
Long-term results. Median follow-up was 3 years
mean 2.5  1.2 years; range, 0-4.8 years). Table IV
ummarizes the details of deaths, major and minor adverse
vents, and reinterventions in the two groups.
Survival. In addition to the 3 postoperative deaths,
6 patients died during follow-up. There was no differ-
nce in the cumulative survival rates between OSR and
VAR according to the log-rank test (P  .24), with
6.5%  1.5% vs 95.2%  1.8% at 1 year and 86.7% 
.4% vs 86.3%  3.4% at 3 years, respectively.
Deaths were related to the aneurysm or to the treatment
aneurysm-related mortality) in one patient after OSR (0.6%)
nd in six patients after EVAR (4%; P .14). In the later case,
wo deaths were reported as in the immediate postoperative
ourse, two died of rupture, and the remaining two deaths
ccurred after vascular reinterventions.
Major adverse events. As shown in Fig 2, there was
o difference in the cumulative survival free of death and
ajor adverse events rates between OSR and EVAR, with
5.9% 1.6% vs 93.2% 2.1% at 1 year, and 85.1% 4.5%
s 82.4% 3.7% at 3 years, respectively (P .09). The rates
f myocardial infarction, neurologic complications, and
enal failure were in the same range in the two groups.
R, Endovascular aneurysm repair.here were three ruptures in the EVAR group, all2 years
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May 20111170 Becquemin et alafter EVAR: two patients had documented endoleaks (one
type I and one type II) which were awaiting treatment, and
one patient ruptured 2 months after a normal CT scan due
Table I. Patient characteristics
Variablea
Open repair EVAR
(n  149) (n  150)
Risk factors
Age, years 70  7.1 68.9  7.7
Range 54-83 49-83
Male sex 146 (98) 151 (100)
Diabetes 29 (19.5) 20 (13.3)
Tobacco 74 (49.7) 73 (48.7)
Hypertension 95 (63.8) 99 (66.0)
Hyperlipidemia 98 (65.8) 103 (68.7)
Carotid artery disease 12 (8.1) 12 (8.0)
Coronary disease
0 84 (56.4) 101 (67.3)
1 40 (26.8) 37 (24.3)
2 25 (16.8) 12 (8.0)
Renal insufficiency 15 (10.1) 21 (14)
Pulmonary disease 42 (28.2) 29 (19.3)
SVS/AAVS risk 1.65  0.51 1.51  0.53
ASA classification
1 12 16
2 89 99
3 48 34
4 — 2
AAA classification
Type A 48 50
Type B 52 56
Type C 16 17
Type D 21 17
Type E 4 6
Type F  saccular 1 —
Type G  iliac 6 5
AAA diameter,b mm 55.6  6.6 55.2  8.1
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiol-
ogists; EVAR, endovascular aneurysm repair; SVS/AAVS, Society for Vas-
cular Surgery/American Association for Vascular Surgery.
aCategoric data are presented as number (%) and continuous data as
means  standard deviation and as noted.
bExcluding 11 iliac aneurysms.
Table II. Details of aneurysm repair
Variablea
Open repair EVAR
P(n  149) (n  150)
Length of
intervention,
hours 2.8  1.1 2.1  0.9 .0001
X-ray exposure time,
minutes 1.9  7.2 16.3  13.5 .0001
Contrast volume, mL 13  46 131  101 .0001
Ventilatory support,
hours
8  13.7 3.2  2.5 .0001
Median 5.5 3.0
RBC transfusion, U 2.1  4.0 0.2  0.9 .0001
Median 2.0 0
EVAR, Endovascular aneurysm repair; RBC, red blood cells.
aData are presented as mean  standard deviation, unless otherwise indi-
cated.to a sudden disconnection between the distal limb of the eraft and the recipient iliac artery. All three patients under-
ent emergency aortic repair: one patient died postopera-
ively, one patient died at 4 months, and one patient
urvived.
Reinterventions. Fig 3 shows that there was a signif-
cant difference in the cumulative survival free of death and
ascular reintervention rates—including graft replacement
nd endovascular or open repair of endoleaks, occlusions or
tenoses—between OSR and EVAR, with 96.5% 1.5% vs
1.3% 2.3% at 1 year and 85.8% 4.5% vs 76.1% 4.6%
t 3 years, respectively (P  .01). In the EVAR group, the
rude percentage of vascular reintervention rate was higher
2.7% vs 16%, P  .0001) with a trend toward a higher
neurysm-related mortality (0.7% vs 4%; P  .12).
Minor complications. There was no significant differ-
able III. In-hospital postoperative data
ariablea
Open repair EVAR
P(n  149) (n  150)
ength of stay, days 10.4  8.3 5.8  5.5 .0001
Median 8.0 5.0 . . .
0-day deaths (all causes) 1 (0.6) 2 (1.3) NS
ajor adverse events,
patientsb 1 (0.6) 3 (2) NS
Acute MI 1 1 . . .
Paraplegia . . . 1 . . .
Renal failure . . . 1 . . .
Stroke . . . 1b . . .
einterventions, patients 2 (1.3) 8 (5.3) NS
VAR, Endovascular aneurysm repair; MI, myocardial infarction.
Continuous data are shown as mean  standard deviation and median;
ategoric data are number (%).
Five complications occurred in 4 patients in the EVAR arm, and this patient
lso had renal failure.
able IV. All outcome measures in study patients
ariable
Open repair EVAR
P
(n  149) (n  150)
No. (%) No. (%)
eaths 12 (8) 17 (11.3) NS
ajor adverse events 6 (4) 10 (6.7) NS
Stroke 1 (0.7) 1 (0.7) NS
Myocardial infarction 4 (2.7) 6 (4) NS
Paraplegia . . . 1 (0.7) NS
Renal failure 1 (0.7) 3 (2) NS
AAA rupture . . . 3 (2.0) NS
Reinterventions 4 (2.7) 24 (16) .0001
inor adverse events 73 (48.7) 62 (41.3) NS
Hemorrhage 7 (4.7) 4 (2.7) NS
Infection 11 (7.4) 14 (9.3) NS
Minor cardiac complications 19 (12.8) 9 (6) .05
Respiratory complications 8 (5.4) 5 (3.3) NS
Atheroembolism 1 (0.7) 3 (2) NS
Graft infection 1 (0.7) . . . NS
Lymphorrhea/lymphocele . . . 4 (2.7) NS
Incisional complications 38 (25.5) 1 (0.7) .0001
Buttock claudication 3 (2) 21 (14) .001
Sexual dysfunction 11 (7.4) 7 (4.7) NSnce in minor complications between OSR and EVAR.
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Volume 53, Number 5 Becquemin et al 1171However, the OSR group experienced more minor cardiac
and incisional complications, whereas buttock claudication
was more frequent in the EVAR group. Of the incisional
complications in the OSR group, 36.3% (29 of 80) oc-
curred after a transperitoneal approach and 17.6% (9 of 51)
after a retroperitoneal approach. Buttock claudication was
Fig 2. Kaplan-Meier curve of survival free of death or major
events after open surgical repair (OSR) or endovascular aneurysm
repair (EVAR).
Fig 3. Kaplan-Meier curve of survival free of death or reinterven-
tion after open surgical repair (OSR) or endovascular aneurysm
repair (EVAR).mostly observed in patients with types C, D, E, or G Sneurysms, in whom the hypogastric artery was coil embo-
ized or lost (14 of 45 [31%]).
Endoleaks. CT scan found endoleaks in 41 of 150
atients (27%) in the EVAR arm. Among 10 type I en-
oleaks, 2 were treated by open surgery and graft replace-
ent, 5 were successfully treated by an endoluminal pro-
edure, and 3 were awaiting treatment at the time of this
nalysis. Of 31 type II endoleaks, 8 were treated by coil
mbolization, and 23 were left untreated.
Sexual function. Sexual assessment 1 year after treat-
ent showed no difference between the two treatments
Table IV), although there was a trend toward more sexual
ysfunction in the OSR group.
Given the crossover rate, a per-protocol analysis was
erformed but did not change the conclusions.
ISCUSSION
The ACE trial shows that EVAR or OSR in low-risk to
oderate-risk patients carries a similar risk of early-term
nd medium-term (up to 4.8 years) death, major adverse
vents, and minor complications. However, EVAR was
ssociated with more vascular reinterventions and a trend
oward higher aneurysm-related mortality.
Three RCTs2-4 have reported lower 1-month postop-
rative mortality rates after EVAR compared with OSR
difference range, 2.5%-4.1%). Accordingly, the propensity
core-matched analysis of a 45,660 cohort of Medicare
atients confirmed a reduction in the postoperative mortal-
ty after EVAR (1.2% vs 4.8%).10 In ACE, we did not find
uch a reduction after EVAR: the postoperative mortality
ate was very low in the OSR group, whereas mortality after
VAR was in the same range as the three previous RCTs
0.5% to 2.1%). After OSR, a similar low mortality rate of
% was found in Veterans Affairs Open versus Endovascular
epair (OVER) trial,2 in control groups of the U.S. Food
nd Drug Administration phase 2 trials (range, 0%-
.7%),11-13 and in centers of excellence,14,15 but the rate
as 4.1% in Dutch Randomised Endovascular Aneurysm
anagement (DREAM)4 trial and 6.2% in the Comparison
f Endovascular Aneurysm Repair with Open Repair in
atients with Abdominal Aortic Aneurysm (EVAR 1) trial.3
Among numerous factors potentially accounting for dif-
erences in mortality rates, study design, population studied,
election of centers, national standards of care, and date of
ublication may be relevant. Although most patients in the
hree previous RCTs were fit for surgery, baseline characteris-
ics may not be fully identical, and a similar distribution of risk
actors does not fully take into account the association of risks.
he OVER trial used the RAND surgical risk score, with only
3% patients categorized as at low risk for surgery. Patients in
VAR 1 or DREAM may have been at higher risk for OSR
ecause risk assessment was left to each center team’s appre-
iation.
We chose the SVS/AAVS grading system. Although it
ay be less accurate than scoring systems such as the Physio-
ogical andOperative Severity Score for enUmeration ofMor-
ality andMorbidity (POSSUM) score,16 Glasgow Aneurysm
core,17 or the fitness score proposed by the EVAR-1 trial-
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May 20111172 Becquemin et alists,18 it may have excluded severe risk factors such as renal,
cardiac, or pulmonary insufficiencies more efficiently than
previous trials. As in the OVER trial, and by hazard of enroll-
ment, fewer women were enrolled which may affect the gen-
eralization of the results. More favorable results after OSR
may also be explained by the size of aneurysms in the ACE
trial, smaller than EVAR 1, but similar to OVER and
DREAM. However, results of the OVER trial suggest a very
limited role of AAA diameter on the early outcome in the
population studied in those RCTs. Finally, the favorable anat-
omy for EVARof all randomized patients alsomeans an easier
and more straightforward open surgical repair.
Volume and qualification of centers are important to
successfully deal with postoperative complications.19 The vol-
ume threshold is about 30 cases/year.20,21 A review of 3912
patients undergoing AAA repair22 found postoperative mor-
tality was 2.2% for vascular surgeons, 4% for cardiac surgeons,
and 5.5% for general surgeons (P  .001). In the frame of
RCTs, it is difficult to compare centers: in ACE, as in OVER,
OSRwas performed by full-time vascular surgeons, but in the
EVAR1 trial, although a fewhighly trained centers performed
EVAR, OSR was also performed by general surgeons.
DREAM and EVAR-1 trialists enrolled patients between
1999 and2003,OVER started in 2002, andACE in2003:we
cannot exclude that improvement in patients’ preoperative,
intraoperative, and postoperative management affected mor-
tality reduction.
As reported in previous RCTs and defined in practice
guidelines,23 blood loss, need for transfusion, duration of
postoperative mechanical ventilation, and hospital length of
stay were significantly lower in the EVAR group. However,
wedidnot find a significant reductionof postoperative general
complication rates between the two treatments. Of note, the
length of stay after both techniques was longer than usually
reported in the United States. This had more to do with the
difference in the health care system and behaviors of patients
andphysicians thanwith the occurrence of complications. The
length of stay was much shorter with EVAR.
Survival, with a median follow-up of 3 years (up to 4.8
years) did not differ between the two treatments options.
These results, consistent with the 2-year results of the
DREAM4 and OVER2 trials and the 4-year results of
EVAR-1,3 are confirmed by recent reports of, respectively, 6
and 8 years of follow-up for DREAM24 and EVAR-1.25 The
expected less invasiveness of EVAR did not translate into a
significant reduction of death or of major adverse events,
which is also in agreement with the OVER trial findings. In
other words, low-risk and intermediate-risk patients sustain
well the more aggressive treatment of OSR.
AAA ruptures remain the Achilles’ heel of EVAR.Despite
a thorough follow-up, three ruptures (2%) occurred in the
EVAR arm, leading to two deaths despite emergency inter-
vention. Two ruptures may have been prevented by more
expedient treatment of identified endoleaks and in the third
patient by a longer limb overlap in the common iliac artery.
TheOVER trial did not report any rupture, but follow-upwas
shorter (1.8 years). TheDREAM24 trial reported one rupture
before treatment, and the possibility of rupture in two patients sho died after EVAR was considered but not proven.
VAR-1 reported 13 ruptures: 10 before treatment, and 3
fter treatment (2 after EVAR, 1 after OSR).
The distribution of recorded complications differed ac-
ording to treatment: more buttock claudication occurred
fter EVAR and more incisional complications after OSR.
uttock claudication is a well-known complication of over-
apping hypogastric arteries by the limb of a stent graft
hen the aneurysm extends close to or involves the
ypogastric bifurcation. Although spontaneous im-
rovement can be expected over time, we previously
eported that 15% of patients remain disabled despite
ehabilitation.26 The patency of the hypogastric artery
hould be maintained, whenever feasible, in healthy pa-
ients, especially those who have normal walking activity,
uch as most of the patients in this trial. At present, this
ay be achieved by inserting currently available large
istal limbs in the common iliac artery or by using
ranched stent grafts in selected cases.27
Incisional complications are frequent after OSR and seem
ore frequent in patients with AAA than in patients with
cclusive disease.28 In the OVER trial, 5% of patients in the
SR group underwent incision hernia repair. Similarly to
VAR-1 and DREAM, we did not record specifically all
bdominal wall repairs or the incidence of bowel obstruction.
hat 24% of the patients in our OSR group presented inci-
ional complications underlines one drawback of the open
pproach. Finally, the higher rate of minor cardiac complica-
ions in the OSR group may be related to a higher rate of
oronary disease in this group or to the more invasive proce-
ure, or both.
Similar to the OVER trial, where 12% of EVAR patients
nderwent a vascular reintervention vs 1.6% in the OSR
roup, in the ACE trial, vascular reinterventions occurred in
6% of the EVAR group vs 2.7% in the OSR group. In
VAR-1, the overall rates of graft-related complications and
einterventions were higher by a factor of three to four in the
ndovascular group. However, indications for reintervention
ere highly variable: rupture, thrombosis, or type I endoleak
ere indications for reintervention, whereas the need for
eintervention in type II endoleaks was still debated. The
REAM24 investigators rightly stated that reintervention
s a “soft” end point because the decision is at the surgeon’s
iscretion.
Finally the lack of significant difference in sexual function
mpairment between OSR and EVAR in ACE trial is consis-
ent with the OVER2 and DREAM29 findings.
One weakness of this study was the slow pace of enroll-
ent and the failure to reach the expected number of patients.
his may have affected the power of the analysis, as may have
een the case in the DREAM trial, which was of a similar
agnitude. Except for the early mortality rates, however, our
ndings were in agreement with the three previous RCTs. A
eta-analysis of these four trials may help to clarify the relative
ndication of EVAR and open surgery in AAA patients.
Finally, these results, as those of previous trials, reflect
urrent stent graft technology. With continuous advances in
tent graft design, it may be possible, as shown by the Euro-
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Volume 53, Number 5 Becquemin et al 1173pean Collaborators on Stent-Graft Techniques for AAA and
Thoracic Aortic Aneurysm and Dissection Repair (EURO-
STAR) results,30 that the durability of EVAR will improve in
the future.
CONCLUSIONS
In a selected group of patients with low to intermediate
risk factors, OSR and EVAR offer no difference in survival or
in major and minor complications. The choice between OSR
and EVAR should rely on the balance of different risks: more
postoperative transfusions, a longer hospital stay, and inci-
sional complications with OSR vs the need of follow-up with
repeat CT scans, a higher rate of vascular reinterventions, and
a small but persistent risk of rupture with EVAR.
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